{
    "clinical_study": {
        "@rank": "21570", 
        "arm_group": [
            {
                "arm_group_label": "LY2940094", 
                "arm_group_type": "Experimental", 
                "description": "40 milligram (mg) administered orally by capsule once daily for 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered orally by one capsule once daily for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the efficacy, safety, and tolerability of a 40 mg once-daily (QD)\n      dose of LY2940094 for 8 weeks in participants with MDD."
        }, 
        "brief_title": "Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of Major Depressive Disorder (MDD) without psychotic features as\n             defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,\n             Text Revision (DSM-IV-TR)\n\n          -  Have clinically significant depressive symptoms defined by a GRID HAMD17 Total score\n             \u226520 at screening\n\n          -  Body mass index (BMI) between 18 and 35 kilogram per square meter (kg/m^2)\n\n        Exclusion Criteria:\n\n          -  Have a current or previous diagnosis of bipolar I or II disorder, MDD with psychotic\n             features, schizoaffective disorder, schizophrenia, or other psychotic disorder\n\n          -  Currently meeting the criteria of treatment-resistant depression defined as \u22652\n             documented, failed treatment trials of adequate dose and duration with a registered\n             antidepressant during the current depressive episode\n\n          -  Had electroconvulsive treatment, transcranial magnetic stimulation, vagal nerve\n             stimulation for symptoms of depression in the 6 months prior to screening\n\n          -  Have any clinically significant medical or uncontrolled condition or circumstance\n             prior to randomization that could affect participant safety"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724112", 
            "org_study_id": "14791", 
            "secondary_id": "I5J-MC-NOAC"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2940094", 
                "description": "Administered orally", 
                "intervention_name": "LY2940094", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33334"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "University Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34201"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prairie Village", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66206"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87109"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10312"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clinton", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84015"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98007"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to Week 8 on the GRID Hamilton Depression Rating Scale 17 Item Version (GRID-HAMD17) Total Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants Responding to Treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 8"
            }, 
            {
                "measure": "Proportion of Participants who Achieved Remission", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Change from Baseline to Week 8 in Maier-Philipp Subscale (MPS) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline,Week 8"
            }, 
            {
                "measure": "Clinical Global Impression - Improvement (CGI-I) Score at Week 8", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Change from Baseline to Week 8 in the Clinical Global Impression - Severity (CGI-S) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }, 
            {
                "measure": "Change from Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HAM-A) Total Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4"
            }, 
            {
                "measure": "Change from Baseline to Week 8 in the Hospital Anxiety and Depression Scale (HADS) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }, 
            {
                "measure": "Population Pharmacokinetic (PK) Model: Estimate of LY2940094 Area Under the Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 8 Weeks of Treatment"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}